GRCL
Gracell Biotechnologies Inc.
NASDAQ: GRCL · HEALTHCARE · BIOTECHNOLOGY
$10.25
+0.00% today
Updated 2026-06-05
Market cap
$989.87M
P/E ratio
—
P/S ratio
732.21x
EPS (TTM)
$-0.97
Dividend yield
—
52W range
$307 – $617
Volume
6.4M
Gracell Biotechnologies Inc. (GRCL) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | $148.52M | $412.22M | $964.95M | $2.06B | $1.66B |
| Cash & equivalents | $11.89M | $312.06M | $754.31M | $1.83B | $1.45B |
| Current assets | $127.96M | $340.35M | $815.47M | $1.89B | $1.50B |
| Total liabilities | $146.13M | $156.86M | $145.29M | $232.77M | $280.51M |
| Current liabilities | $7.44M | $18.17M | $93.36M | $155.12M | $220.64M |
| Long-term debt | $138.69M | $138.69M | $51.93M | $54.35M | $46.51M |
| Shareholder equity | $2.38M | $255.36M | $819.66M | $1.83B | $1.38B |
| Retained earnings | $-81.09M | $-289.40M | $-564.03M | $-1.02B | $-1.63B |
| Accounts receivable | $6.20M | $13.77M | $30.96M | $40.69M | $26.33M |
| Inventory | $7.70M | $9.39M | $-30.96M | $8.70M | $-26.33M |
| Goodwill | — | — | — | — | — |
Frequently asked questions
Is GRCL's balance sheet healthy?
GRCL holds $1.45B in cash and equivalents against $46.51M in long-term debt, on $1.38B of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.